Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved February 12, 2026, awarding 76,701 restricted stock units to 34 new employees.
One-fourth of each employee grant vests on February 16, 2027, then one-twelfth of the remainder vests quarterly thereafter, subject to continued employment. Grants were made under the company's Plan and Nasdaq Listing Rule 5635(c)(4).
BridgeBio (Nasdaq: BBIO) will report its fourth quarter and full year 2025 financial results and provide a business update after market close on February 24, 2026. The company will host a conference call and live webcast at 4:30 pm ET the same day. A replay will be available on the investor website for 30 days.
BridgeBio (Nasdaq: BBIO) reported positive Phase 3 PROPEL 3 topline results for oral infigratinib in children with achondroplasia. Key wins: AHV treatment difference +1.74 cm/year (LS mean), mean difference +2.10 cm/year; height Z‑score +0.41 SD; first statistically significant improvement in body proportionality in children 8 years.Oral infigratinib was well tolerated, with no drug‑related discontinuations and three mild, transient cases (4%) of hyperphosphatemia. NDA/MAA planned H2 2026; Breakthrough Therapy designation maintained.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved January 23, 2026, to 11 new employees totaling 31,428 restricted stock units.
One-fourth of each award vests on February 16, 2027, then one-twelfth of the remaining shares vests quarterly thereafter, subject to continued employment. Awards were granted under the Amended and Restated 2019 Inducement Equity Plan.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved January 23, 2026 for 12 new employees totaling 34,199 restricted stock units. Awards were granted under the company's Amended and Restated 2019 Inducement Equity Plan.
Vesting: one‑quarter of each employee's RSUs vest on November 16, 2026, then one‑twelfth of the remaining shares vest quarterly thereafter, subject to continued employment. The Plan was originally adopted in November 2019 and amended and restated on February 10, 2023 and December 13, 2023. Grants were made as inducements pursuant to Nasdaq Listing Rule 5635(c)(4).
BridgeBio (Nasdaq: BBIO) priced $550 million of 0.75% convertible senior notes due Feb 1, 2033, with an initial purchaser option for an additional $82.5 million. The company estimates net proceeds of approximately $538.4 million (or ~$619.3 million if the option is exercised) and expects to close on Jan 21, 2026. The notes carry an initial conversion rate of 9.0435 shares per $1,000 (≈$110.58 per share), a ~45% premium to the $76.26 last sale price on Jan 15, 2026. BridgeBio intends to use proceeds to prefund repurchase or repayment of its 2.50% notes due 2027 and for general corporate purposes, and concurrently agreed to repurchase ~1.1 million shares for ~$82.5 million.
BridgeBio (Nasdaq: BBIO) intends to offer $550 million aggregate principal amount of convertible senior notes due 2033, with an initial purchaser option for an additional $82.5 million. The company plans to use net proceeds to repurchase, settle conversion obligations in respect of, or repay a portion of its 2.50% convertible senior notes due 2027 and for general corporate purposes. The notes will bear interest semi-annually, mature on February 1, 2033, and may be convertible into cash, shares or a combination, with conversion and redemption terms determined at pricing. The company also intends to use up to $82.5 million cash to repurchase common shares concurrently with pricing.
BridgeBio (NASDAQ: BBIO) reported preliminary unaudited Q4 2025 Attruby revenue of $146.0M and FY 2025 Attruby revenue of $362.4M, with 6,629 unique patient prescriptions written by 1,632 prescribers as of Dec 31, 2025. The company announced a new TTR amyloid‑depleting antibody program targeting ATTR‑CM expected to enter the clinic in 2027–2028. An interim FORTIFY analysis for BBP‑418 in LGMD2I/R9 showed a 2.6‑point NSAD benefit versus placebo at 12 months and prompted FDA guidance to orient the NDA toward traditional full approval; BridgeBio plans to submit the BBP‑418 NDA in H1 2026. BridgeBio expects an NDA submission for encaleret in ADH1 in H1 2026, will initiate RECLAIM‑HP in summer 2026, and reported LPLV for PROPEL 3 with topline due by end of Q1 2026. Cash and equivalents were approximately $587.5M as of Dec 31, 2025.
BridgeBio (Nasdaq: BBIO) said co-founder and CEO Neil Kumar, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 7:30 am PT. Investors may watch a live webcast via the company’s Investors > Events & Presentations page at http://investor.bridgebio.com. A replay will be available on the company website for 30 days after the presentation.
BridgeBio (Nasdaq: BBIO) will host an investor webinar on Friday, January 9, 2026 at 8:00 am ET featuring Janet Legare, M.D., investigator in the registrational Phase 3 PROPEL 3 study of infigratinib for children with achondroplasia.
Dr. Legare will overview achondroplasia pathophysiology, current unmet need, and the rationale for evaluating infigratinib. Executive members of the skeletal dysplasia program will review the infigratinib clinical program and the ongoing PROPEL 3 study, with topline results expected in Q1 2026.
The live webcast is available via the company’s Events & Presentations page and a replay will be posted for 30 days.